Joel Yates

• Kumaraswamy A, Duan Z, Flores D, Zhang C, Sehrawat A, Hu YM, Swaim OA, Rodansky E, Storck WK, Kuleape JA, Bedi K, Mannan R, Wang XM, Udager A, Ravikumar V, Bankhead A 3rd, Coleman I, Lee JK, Morrissey C, Nelson PS, Chinnaiyan AM, Rao A, Xia Z, Yates JA, & Alumkal JJ. LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function. JCI Insight (2023). DOI: 10.1172/jci.insight.167440

• Westbrook TC, Guan X, Rodansky E, Flores D, Liu CJ, Udager AM, Patel RA, Haffner MC, Hu YM, Sun D, Beer TM, Foye A, Aggarwal R, Quigley DA, Youngren JF, Ryan CJ, Gleave M, Wang Y, Huang J, Coleman I, Morrissey C, Nelson PS, Evans CP, Lara P, Reiter RE, Witte O, Rettig M, Wong CK, Weinstein AS, Uzunangelov V, Stuart JM, Thomas GV, Feng FY, Small EJ, Yates JA, Xia Z, & Alumkal JJ. Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity. Nature Communications (2022). DOI: 10.1038/s41467-022-32701-6

• Kim DH, Sun D, Storck WK, Welker Leng KR, Jenkins C, Coleman DJ, Sampson DA, Guan X, Kumaraswamy A, Rodansky ES, Urrutia JA, Schwartzman J, Zhang C, Beltran H, Labrecque MP, Morrissey C, Lucas JM, Coleman I, Nelson PS, Corey E, Handelman SK, Sexton JZ, Aggarwal R, Abida W, Feng FY, Small EJ, Spratt DE, Bankhead III A, Rao A, Gesner EM, Attwell S, Lakhotia S, Campeau E, Yates JA, Xia Z, & Alumkal JJ. BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program. Clinical Cancer Research (2021). DOI: 10.1158/1078-0432.CCR-20-4968

• Coleman DJ, Sampson DA, Sehrawat A, Kumaraswamy A, Sun D, Wang Y, Schwartzman J, Urrutia J, Lee AR, Coleman IM, Nelson PS, Dong X, Morrissey C, Corey E, Xia Z, Yates JA, & Alumkal JJ. Alternative splicing of LSD1+8a in neurodendocrine prostate cancer is mediated by SRRM4. Neoplasia (2020). DOI: 10.1016/j.neo.2020.04.002

• Little AC, Kovalenko I, Goo LE, Hong HS, Kerk SA, Yates JA, Purohit V, Lombard DB, Merajver SD, & Lyssiotis CA. High-content fluorescence imaging with the metabolic flux assay reveals insights into mitochondrial properties and functions. Communications Biology (2020). DOI: 10.1038/s42003-020-0988-z

• Little AC, Pathanjeli P, Wu ZF, Bao LW, Goo LE, Yates JA, Oliver CR, Soellner MB, & Merajver SD. IL-4/IL-13 Stimulated Macrophages Enhance Breast Cancer Invasion Via Rho-GTPase Regulation Of Synergistic VEGF/CCL-18 Signaling.  Frontiers in Oncology (2019). DOI: 10.3389/fonc.2019.00456

• Oliver CR, Altemus MA, Westerhof TM, Cheriyan H, Cheng X, Dziubinski M, Wu Z, Yates JA, Morikawa A, Heth J, Castro MG, Leung BM, Takayama S, & Merajver SD. A platform for artificial intelligence bases identification of the extravasation potential of cancer cells into the brain metastatic niche. Lab on a Chip (2019). DOI: 10.1039/c8lc01387j

• Wynn ML, Yates JA, Evans CR, Van Wassenhove L, Wu ZF, Bridges S, Bao L, Fournier C, Ashrafzadeh S, Merrins MJ, Satin LS, Schnell S, Burant CF, Merajver SD. RhoC is a Potent Regulator of Glutamine Metabolism and N-acetylaspartate Production in Inflammatory Breast Cancer Cells. ​Journal of Biological Chemistry (2016). DOI: 10.1074/jbc.M115.703959

Full publication list available on PubMed or Google Scholar.